Tracey O'Connor

MD
Medical Oncology
2022 Buffalo Spree Top Docs badge

Dr. O'Connor is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2022

Specializing In:

Breast cancer

Special Interests:

Novel treatments for breast cancer Psychological impact of breast cancer Supportive care therapies for patients with advanced disease Survivorship issues and breast cancer

About Tracey O'Connor

Positions

Roswell Park Comprehensive Cancer Center

  • Associate Professor, Department of Medicine

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

  • Associate Professor of Clinical Medicine

Background

Education and Training:

  • MD - School of Medicine and Biomedical Sciences, State University of New York at Buffalo
  • BS - Northwestern University, Evanston, IL

Residency:

  • Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY

Fellowship:

  • Roswell Park Cancer Institute, Buffalo, NY

Board Certification:

  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Learn More
Exercise in Improving Health and Quality of Life in Breast Cancer Survivors
Learn More

Clinical Trials

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Learn More
Exercise in Improving Health and Quality of Life in Breast Cancer Survivors
Learn More
Breast cancer at 30: Danielle's story What Is Metastatic Breast Cancer? Breast Cancer in Men: Owen’s Story Dying with Dignity Staying on Endocrine Therapy After Breast Cancer When Breast Cancer Becomes Metastatic

Featured on Cancer Talk

Breast cancer at 30: Danielle's story
What Is Metastatic Breast Cancer?
Breast Cancer in Men: Owen’s Story

Showing all3 of 6

Publications

Full Publications list on PubMed
  • Lang JK, Karthikeyan B, Quiñones-Lombraña A, Hageman-Blair R, Early AP, Levine EG, Sharma UC, Blanco JG & O’Connor T. (2021). CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin. Cardio Oncology, 7(1): 17. PMID: 33975650, PMCID: PMC8111996 
  • Magnuson A, Sedrak MS, Gross CP, Tew WP, Klepin HD, Wildes TM, Muss HB, Dotan E, Freedman RA, O'Connor T, Dale W, Cohen HJ, Katheria V, Arsenyan A, Levi A, Kim H, Mohile S, Hurria A & Sun CL. (2021). Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early- Stage Breast Cancer. J Clin Oncol, 39(6):608-618. PMID: 33444080
  • Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O’Connor T, Velasco Jr MR, Weckstein D, O’Mara A, Loprinzi CL & Shapiro CL. (2017). Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients with Bone Metastases: A Randomized Clinical Trial. JAMA, 317(1):48-58. PMID: 28030702, PMCID:  PMC5321662
  • O’Connor TL, Ngamphaiboon N, Groman A, Luczkiewicz DL, Kuszczak SM, Grant PC & Kerr CW. (2015).   Hospice Utilization and End-of-Life Care in Metastatic Breast Cancer Patients at a Comprehensive Cancer Center. J Pall Med, 18(1):50-55. PMID: 25353618
  • O’Connor TL, Edge SB, Kossoff EB, Groman A, Wilding GE, Ademuyiwa FO, Levine EG, Watroba N & Ngamphaiboon N. (2012). Factors affecting the delivery of adjuvant/neoadjuvant chemotherapy in older women with breast cancer. Journal of Geriatric Oncology, 3(4):320-328.